TY - JOUR
T1 - Acute respiratory viral adverse events during use of antirheumatic disease therapies
T2 - A scoping review
AU - Kilian, Adam
AU - Chock, Yu Pei
AU - Huang, Irvin J.
AU - Graef, Elizabeth R.
AU - Upton, Laura A.
AU - Khilnani, Aneka
AU - Krupnikova, Sonia D.Silinsky
AU - Almaghlouth, Ibrahim
AU - Cappelli, Laura C.
AU - Fernandez-Ruiz, Ruth
AU - Frankel, Brittany A.
AU - Frankovich, Jourdan
AU - Harrison, Carly
AU - Kumar, Bharat
AU - Monga, Kanika
AU - Vega, Jorge A.Rosario
AU - Singh, Namrata
AU - Sparks, Jeffrey A.
AU - Sullo, Elaine
AU - Young, Kristen J.
AU - Duarte-Garcia, Ali
AU - Putman, Michael
AU - Johnson, Sindhu
AU - Grainger, Rebecca
AU - Wallace, Zachary S.
AU - Liew, Jean W.
AU - Jayatilleke, Aruni
N1 - Funding Information:
The COVID-19 Global Rheumatology Alliance receives financial support from Amgen and Janssen (Johnson & Johnson) . This project was planned and completed prior to receipt of any funding.
Funding Information:
The COVID-19 Global Rheumatology Alliance receives financial support from Amgen and Janssen (Johnson & Johnson). This project was planned and completed prior to receipt of any funding.
Publisher Copyright:
© 2020 Elsevier Inc.
PY - 2020/10
Y1 - 2020/10
N2 - Introduction: COVID-19 is an acute respiratory viral infection that threatens people worldwide, including people with rheumatic disease, although it remains unclear to what extent various antirheumatic disease therapies increase susceptibility to complications of viral respiratory infections. Objective: The present study undertakes a scoping review of available evidence regarding the frequency and severity of acute respiratory viral adverse events related to antirheumatic disease therapies. Methods: Online databases were used to identify, since database inception, studies reporting primary data on acute respiratory viral infections in patients utilizing antirheumatic disease therapies. Independent reviewer pairs charted data from eligible studies using a standardized data abstraction tool. Results: A total of 180 studies were eligible for qualitative analysis. While acknowledging that the extant literature has a lack of specificity in reporting of acute viral infections or complications thereof, the data suggest that use of glucocorticoids, JAK inhibitors (especially high-dose), TNF inhibitors, and anti-IL-17 agents may be associated with an increased frequency of respiratory viral events. Available data suggest no increased frequency or risk of respiratory viral events with NSAIDs, hydroxychloroquine, sulfasalazine, methotrexate, azathioprine, mycophenolate mofetil, cyclophosphamide, or apremilast. One large cohort study demonstrated an association with leflunomide use and increased risk of acute viral respiratory events compared to non-use. Conclusion: This scoping review identified that some medication classes may confer increased risk of acute respiratory viral infections. However, definitive data are lacking and future studies should address this knowledge gap.
AB - Introduction: COVID-19 is an acute respiratory viral infection that threatens people worldwide, including people with rheumatic disease, although it remains unclear to what extent various antirheumatic disease therapies increase susceptibility to complications of viral respiratory infections. Objective: The present study undertakes a scoping review of available evidence regarding the frequency and severity of acute respiratory viral adverse events related to antirheumatic disease therapies. Methods: Online databases were used to identify, since database inception, studies reporting primary data on acute respiratory viral infections in patients utilizing antirheumatic disease therapies. Independent reviewer pairs charted data from eligible studies using a standardized data abstraction tool. Results: A total of 180 studies were eligible for qualitative analysis. While acknowledging that the extant literature has a lack of specificity in reporting of acute viral infections or complications thereof, the data suggest that use of glucocorticoids, JAK inhibitors (especially high-dose), TNF inhibitors, and anti-IL-17 agents may be associated with an increased frequency of respiratory viral events. Available data suggest no increased frequency or risk of respiratory viral events with NSAIDs, hydroxychloroquine, sulfasalazine, methotrexate, azathioprine, mycophenolate mofetil, cyclophosphamide, or apremilast. One large cohort study demonstrated an association with leflunomide use and increased risk of acute viral respiratory events compared to non-use. Conclusion: This scoping review identified that some medication classes may confer increased risk of acute respiratory viral infections. However, definitive data are lacking and future studies should address this knowledge gap.
KW - Adverse event
KW - Antirheumatic medications
KW - COVID-19
KW - Immunosuppressive treatment
KW - Rheumatic disease
KW - SARS-CoV-2
UR - http://www.scopus.com/inward/record.url?scp=85090572566&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85090572566&partnerID=8YFLogxK
U2 - 10.1016/j.semarthrit.2020.07.007
DO - 10.1016/j.semarthrit.2020.07.007
M3 - Review article
C2 - 32931985
AN - SCOPUS:85090572566
SN - 0049-0172
VL - 50
SP - 1191
EP - 1201
JO - Seminars in Arthritis and Rheumatism
JF - Seminars in Arthritis and Rheumatism
IS - 5
ER -